TG Therapeutics Inc TGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TGTX is a good fit for your portfolio.
News
-
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
-
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
-
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
-
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
-
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
-
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
-
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
Trading Information
- Previous Close Price
- $13.99
- Day Range
- $13.26–14.02
- 52-Week Range
- $6.46–35.67
- Bid/Ask
- $13.78 / $14.05
- Market Cap
- $2.13 Bil
- Volume/Avg
- 3.7 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 17.66
- Price/Sales
- 8.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 264
- Website
- https://www.tgtherapeutics.com
Comparables
Valuation
|
Metric
|
TGTX
|
CELC
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.66 | — | — |
Price/Book Value | 13.20 | 2.99 | 3.48 |
Price/Sales | 8.89 | — | 2,160.78 |
Price/Cash Flow | 39.02 | — | — |
Price/Earnings
TGTX
CELC
VRDN
Financial Strength
|
Metric
|
TGTX
|
CELC
|
VRDN
|
|---|---|---|---|
Quick Ratio | 5.00 | 12.78 | 17.93 |
Current Ratio | 5.92 | 13.43 | 18.26 |
Interest Coverage | 2.04 | −12.43 | −137.76 |
Quick Ratio
TGTX
CELC
VRDN
Profitability
|
Metric
|
TGTX
|
CELC
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | 19.44% | −35.57% | −42.76% |
Return on Equity (Normalized) | 54.76% | −49.08% | −82.42% |
Return on Invested Capital (Normalized) | 35.76% | −39.21% | −50.70% |
Return on Assets
TGTX
CELC
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ydpccxbph | Hqgtm | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mrdfwxxy | Zywmvn | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qwvmqkjr | Pwbpc | $98.1 Bil | |
MRNA
| Moderna Inc | Twvytlwx | Dzw | $39.1 Bil | |
ARGX
| argenx SE ADR | Tkdwxmrxg | Cdyr | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Qkztxwxms | Dbkz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pqyrpclb | Pfnyvn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ysjcdvdjh | Bmcvrb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zqkmjklsr | Szxkjb | $12.5 Bil | |
INCY
| Incyte Corp | Wnbrktmg | Rgscl | $11.9 Bil |